Login to Your Account



Connetics Evolves With Soriatane Purchase; Psoriasis Market Grows

By Randall Osborne


Monday, February 23, 2004
Connetics Corp.'s president and CEO Thomas Wiggans called it a "transforming event." Known for Olux and Luxiq, the marketed duo of foams to treat scalp disorders, his company this month entered an agreement to buy exclusive U.S. rights to F. Hoffmann-La Roche Ltd.'s marketed oral psoriasis drug, Soriatane, for $123 million. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription